Sean Hashmi, MD Medical Reviewer Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California
Understanding tirzepatide dosing in units is equally important for accurate cost planning
Intravital imaging of islet Ca 2+ dynamics reveals enhanced cell connectivity after bariatric surgery in mice
We understand the complexities of body mass and weight loss, and we do not determine eligibility solely based on the number on the scale
A prespecified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials demonstrated that significantly more patients treated with Wegovy 2.4 mg SC once weekly had an improvement of at least one New York Heart Association (NYHA) functional class compared to those who received placebo (32.6% versus 21.5%, respectively
These drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other potential risks include: Acute pancreatitis Gallbladder disease (cholelithiasis, cholecystitis) Acute kidney injury Hypersensitivity reactions Patients should be monitored for persistent abdominal pain, changes in renal function, and other signs that may require discontinuation or additional workup
